|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesized that serum concentrations of interleukin-6 (IL6) and lipoprotein-associated phospholipase A2 (LpPLA2) were inversely associated with long-term functional decline independently of vascular risk factors, stroke and myocardial infarction (MI) occurring during follow-up.
|
30934019 |
2019 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we detected the correlation between D166E polymorphism of Lp-PLA2 and myocardial infarction (MI).
|
31115024 |
2019 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
C-terminal FGF-23 was measured in plasma samples using an established enzyme-linked immunosorbent assay system for 4947 patients within 30 days of ACS (median, 14 days) and with 1 additional CV risk factor in the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial of the lipoprotein-associated phospholipase A2 inhibitor darapladib vs placebo performed from December 1, 2009, to April 24, 2014 (median follow-up, 2.5 years).
|
29710336 |
2018 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A2 assessment might be used for MI and CVD death risk prediction.
|
28429599 |
2018 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, we examined the association of rs10846744 with Lp-PLA2 activity, cardiovascular outcomes, and interaction with the Lp-PLA2 inhibitor, darapladib, in the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY) and Stabilization of Plaque using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) studies.
|
30289950 |
2018 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated baseline and change from baseline in Lp-PLA2 activity, two efficacy endpoints (major coronary events and myocardial infarction) as well as tolerability parameters at genome-wide and candidate gene level using a meta-analytic approach.
|
28753643 |
2017 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association between early-onset MI, lipid levels and 20 single nucleotide polymorphisms (SNPs) in the candidate genes ADIPOQ, APOA5, ALOX5AP, CYBA, IL6, LPL, PECAM1, PLA2G2A and PLA2G7, chosen because of previously reported associations with Coronary Heart Disease (CHD) or with CHD risk factors.
|
21130994 |
2011 |
|
Myocardial Infarction
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Although V279F and I198T mutations significantly decreased the activity of Lp-PLA(2), only the promoter rs13210554 polymorphism was associated with MI.
|
19034521 |
2009 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although V279F and I198T mutations significantly decreased the activity of Lp-PLA(2), only the promoter rs13210554 polymorphism was associated with MI.
|
19034521 |
2009 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction.
|
16689754 |
2006 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several studies have confirmed that Lp-PLA2 is an independent risk factor for cardiovascular events (i.e. myocardial infarction and stroke).
|
15990594 |
2005 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe.
|
12801611 |
2003 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To elucidate the relationships among PAF-AH enzyme activity, genotype, age, and atherosclerosis, we assayed these parameters in a large Japanese population (n=3932) that consisted of three groups; a control group (healthy individuals; n=1684), a risk-factor group (individuals having at least one conventional risk factor for atherosclerosis; n=1398), and a diseased group (patients who had suffered a myocardial infarction or stroke; n=850).
|
10781653 |
2000 |